Search Results

By Matthew Stenger  / Tuesday, September 29, 2015 1:20 PM

Study Finds No Disease-Free Survival Improvement With Adjuvant Erlotinib in EGFR-Expressing NSCLC

In the phase III RADIANT trial reported in the Journal of Clinical Oncology, Kelly et al found no disease-free survival improvement with adjuvant erlotinib (Tarceva) vs placebo in patients with EGFR-expressing stage IB to IIIA non–small cell lung cancer (NSCLC). However, there was evidence of ...